Cancer Treatment Centers of America (CTCA) is now moving forward with unique research on the use of novel agents in the battle against cancer. Taking the daring work of Nobel Prize winner Linus Pauling to the next level, researchers are eyeing the impact of high doses of intravenous, or in the vein, Vitamin C on cancer.

The study is being led by Dr. Christopher M. Stephenson, an internal medicine specialist at CTCA Midwestern, Dr. Robert D. Levin, Chief of Medical Oncology at CTCA Midwestern, and Mr. Christopher G. Lis, MPH, Vice President, Research and Development, CTCA.

"This is the first investigational new drug application (IND) approved by the U.S. Food and Drug Administration in the history of CTCA," said Lis. "The first few patients have successfully completed the trial, thanks in large part to our clinical staff, particularly our laboratory, pharmacy, and nursing teams." By Gene Koprowski